Meisner Derek M's Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jan 12, 2026
- Accession no.
- 0001628280-26-001896
- Filed
- Jan 12, 2026
- Trade date
- Jan 8-12, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $90.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meisner Derek MCIK 0001752461 | Officer (Chief Legal Officer & Corp Sec) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Common Stock | SSaleDisposed | −6,819 | $1.82F2 | −$12,410.58 | 127,640 | Direct | |
| Jan 8, 2026 | Common Stock | SSaleDisposed | −30,092 | $1.82F2 | −$54,767.44 | 97,548 | Direct | |
| Jan 9, 2026 | Common Stock | SSaleDisposed | −5,200 | $1.76F4 | −$9,152 | 92,348 | Direct | |
| Jan 12, 2026 | Common Stock | SSaleDisposed | −8,548 | $1.71F5 | −$14,617.08 | 83,800 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.